Gastric Metaplasia, Hypertrophic and Hypersecretory Disorders

1.0 Hypertrophic & Hypersecretory Gastropathies

Disorders of gastric mucosal growth and acid secretion, while individually rare, present unique diagnostic and management challenges in clinical gastroenterology. A strategic approach is crucial for differentiating between these conditions, as their underlying pathophysiology, clinical trajectories, and therapeutic needs are starkly different. This section provides a framework for understanding and managing two classic, yet frequently contrasted, gastropathies: Ménétrier disease and Zollinger-Ellison syndrome.

1.1 Ménétrier Disease

Overview and Pathophysiology

Ménétrier disease is a rare, acquired hypertrophic gastropathy characterized by giant gastric folds. The core pathophysiological mechanism involves the overexpression of Transforming Growth Factor-α (TGF-α), which leads to excessive activation of the Epidermal Growth Factor Receptor (EGFR) on the gastric mucosa. This signaling cascade drives massive hyperplasia of foveolar (mucous) cells, which crowd out and lead to the atrophy of acid-producing parietal cells and enzyme-producing chief cells.

Classic Diagnostic Triad

The hallmark clinical features of Ménétrier disease can be summarized in a classic triad:

• Giant Rugal Folds: Massive, convoluted folds are typically found on endoscopy, predominantly located in the gastric body and fundus.
• Protein-Losing Gastropathy: The hyperplastic, permeable mucosa leads to a significant leakage of plasma proteins, especially albumin, into the gastric lumen. This results in hypoalbuminemia, which manifests clinically as peripheral edema, ascites, and pleural effusions.
• Hypochlorhydria or Achlorhydria: Due to the progressive loss of parietal cells, gastric acid secretion is markedly reduced or absent. This stands in sharp contrast to hypersecretory states like Zollinger-Ellison syndrome.

Diagnostic Workup

A definitive diagnosis is established through a combination of endoscopic, histologic, and laboratory findings.

• Endoscopy (EGD): Upper endoscopy is the initial diagnostic modality, revealing the characteristic enlarged, cerebriform gastric folds. It is essential to obtain biopsies to rule out mimics such as lymphoma or infiltrative carcinoma.
• Histology: A full-thickness mucosal biopsy is required for diagnosis. Histologic examination reveals marked foveolar hyperplasia, glandular atrophy with loss of parietal and chief cells, and cystic dilation of the gastric glands.
• Laboratory Confirmation: Key laboratory findings include low serum albumin and total protein. An elevated stool α-1 antitrypsin clearance confirms the presence of a protein-losing enteropathy.

Management Algorithm

Management is tailored to symptom severity, nutritional status, and the risk of malignant transformation.

• Supportive Care: A high-protein diet is fundamental to counteract ongoing protein loss and support nutritional status. Albumin infusions may be required in cases of severe hypoalbuminemia.
• Targeted Medical Therapy: For refractory cases with severe protein loss, Cetuximab—a monoclonal antibody that blocks EGFR—has shown significant benefit in improving symptoms and biochemical parameters.
• Symptomatic Control: Proton Pump Inhibitors (PPIs) are often used for symptomatic relief of epigastric pain or nausea, though they do not address the underlying pathophysiology.
• Surgical Intervention: A partial or total gastrectomy is reserved for patients with severe, debilitating symptoms refractory to medical therapy, unmanageable protein loss, or the development of gastric adenocarcinoma.
• Cancer Surveillance: Patients with Ménétrier disease have an increased risk of developing gastric adenocarcinoma. Therefore, periodic endoscopic surveillance with biopsies is advised.

This profile of protein loss and low acid secretion provides a critical contrast to Zollinger-Ellison Syndrome, a key differential diagnosis.

1.2 Zollinger-Ellison Syndrome (ZES)

Overview and Pathophysiology

Zollinger-Ellison Syndrome (ZES) is caused by a gastrin-secreting neuroendocrine tumor (NET), known as a gastrinoma. Ectopic and unregulated gastrin secretion leads to massive parietal cell hyperplasia and profound gastric acid hypersecretion. Over 80% of gastrinomas are located within the "gastrinoma triangle," an anatomical region defined by the duodenum, pancreas, and peripancreatic lymph nodes. The duodenum is the most common primary site, followed by the pancreas and peripancreatic lymph nodes.

When to Suspect ZES

A high index of suspicion is required to diagnose ZES. The following clinical scenarios should trigger a diagnostic workup:

• Refractory or recurrent peptic ulcers that fail to heal with standard PPI therapy, especially when H. pylori is negative and NSAID use is excluded.
• Ulcers in atypical locations, such as the distal duodenum or the jejunum, or the presence of multiple simultaneous ulcers.
• The combination of peptic ulcer disease with chronic, unexplained diarrhea or steatorrhea.
• A personal or family history of Multiple Endocrine Neoplasia, Type 1 (MEN1), as approximately 20-25% of ZES cases are associated with this syndrome.

Stepwise Diagnostic Algorithm

The diagnosis of ZES is a sequential process, moving from biochemical confirmation to tumor localization.

• Biochemical Confirmation: The initial step is to measure a fasting serum gastrin level and gastric pH (off acid-suppressing medication). A fasting gastrin level >1000 pg/mL in the presence of a gastric pH <2 is diagnostic of ZES.
• The "Gray Zone" Confirmatory Test: For patients with an intermediate fasting gastrin level (e.g., 200-1000 pg/mL) and a low gastric pH (<2), a secretin stimulation test is required. In ZES, intravenous secretin administration causes a paradoxical and significant rise in serum gastrin (an increase of >120 pg/mL), confirming the diagnosis.
• Tumor Localization: Biochemical confirmation is followed by functional imaging as the first-line localization step, then anatomic imaging for staging, and finally Endoscopic Ultrasound (EUS) for occult tumors. The Ga-68 DOTATATE PET/CT scan is the modern gold standard and most sensitive modality for detecting gastrinomas. Anatomic imaging with CT or MRI is used for staging metastatic disease and surgical planning. EUS is the next best test for identifying small or occult tumors in the pancreas or duodenal wall if functional imaging is negative.

Tiered Management Strategy

The management of ZES is prioritized to first control the life-threatening effects of acid hypersecretion before addressing the underlying tumor.

• Immediate Priority - Acid Control: The first and most critical step is to gain control of gastric acid hypersecretion with high-dose Proton Pump Inhibitors (PPIs). Without PPIs, mortality is primarily from ulcer complications such as bleeding and perforation; therefore, immediate acid control is a life-saving intervention.
• ...